BRAF V600 Mutated-Stage III/IV Melanoma
1 clinical trials · Condition
◉ Watch BRAF V600 Mutated-Stage III/IV Melanoma
| Record | Firm | Date |
|---|---|---|
| Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma (NCT06557291) | Novartis | 2022-10-04 |
Track BRAF V600 Mutated-Stage III/IV Melanoma automatically
Every clearance here is in the API, with alerts when new ones post.